US5011471027 - Common Stock
KRYSTAL BIOTECH INC
NASDAQ:KRYS (5/2/2024, 4:08:46 PM)
After market: 160.23 0 (0%)160.23
+0.56 (+0.35%)
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 210 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the development of redosable gene therapies for patients living with debilitating diseases. The company has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Its platform consists of an engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Its product candidates in various stages of clinical and preclinical development include Vyjuvek for dystrophic epidermolysis bullosa (Dystrophic EB), KB105 for TGM1-deficient autosomal recessive congenital ichthyosis (ARCI), KB104 for Netherton Syndrome, KB407 for Cystic Fibrosis (CF), and KB408 for Alpha-1 antitrypsin deficiency (AATD). Its KB301 is for aesthetic skin conditions. The Company’s subsidiary, Jeune Aesthetics, Inc., which focuses on preclinical and clinical studies for aesthetic skin conditions.
KRYSTAL BIOTECH INC
2100 Wharton St Ste 701
Pittsburgh PENNSYLVANIA 15203
P: 14125865830
CEO: Krish S. Krishnan
Employees: 210
Website: https://www.krystalbio.com/
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced...
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today...
Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model...
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
It will take a lot, but this goal isn't out of reach for these stocks.
Here you can normally see the latest stock twits on KRYS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: